Teva Expands U.S. Biosimilars Portfolio with Samsung Bioepis Deal
Event summary
- Teva secures U.S. commercialization rights for two immunology biosimilars: infliximab-abda and ETICOVO® (etanercept-ykro).
- Infliximab-abda rights transfer to Teva in Q3 2027; ETICOVO® rights transfer at closing, expected by year-end 2026.
- Samsung Bioepis retains regulatory oversight and manufacturing responsibilities.
- Teva will pay Samsung Bioepis an upfront payment over three years, with potential milestone payments.
- Deal expands existing biosimilar collaborations between Teva and Samsung Bioepis.
The big picture
This deal strengthens Teva's position in the biosimilars market, aligning with its 'Pivot to Growth' strategy. The agreement combines Samsung Bioepis' biosimilar expertise with Teva's commercial capabilities, addressing the growing demand for affordable biologic treatments. The U.S. immunology market is highly competitive, with established players like Janssen and Amgen, making successful commercialization critical for Teva's strategic expansion.
What we're watching
- Commercial Execution
- Whether Teva can effectively integrate and commercialize the two biosimilars to capture market share in the competitive U.S. immunology space.
- Regulatory Approvals
- The timeline and conditions for closing the deal, including receipt of necessary regulatory approvals.
- Pipeline Development
- The pace at which Teva and Samsung Bioepis advance their broader biosimilar pipeline, including up to six potential candidates in early-stage development.
Related topics
